**Specifications Table**TableSubject areaClinical and Translational ResearchMore specific subject areaBiomarker Research, Cancer EpidemiologyType of dataTablesHow data was acquiredTumor registry query was followed by vital status ascertainment, and medical records reviewLuminex®- or enzyme-linked immunosorbent assay- based quantitation of adipokines (adiponectin, leptin, C-reactive protein, interleukine-6, interleukine-1β, interleukine-1Ra, tumor necrosis factor-α, and C-peptide) from plasma samples was conducted.A Luminex®200^TM^ instrument with Xponent 3.1 software was used to acquire all data except for C-reactive protein determinations which have been done using a Synergy 2 BioTek multi-mode readerData formatAnalyzedExperimental factorsAdipokines were determined from the corresponding plasma samples collected at the time of breast cancer diagnosisExperimental featuresThe dataset included 97 adult females with diabetes mellitus and newly diagnosed breast cancer (cases) and 194 matched controls (breast cancer only). Clinical and treatment history were evaluated in relationship with cancer outcomes and adipokine profiles. A biomarker correlation analysis was also performed.Data source locationUnited States, Buffalo, NY - 42° 53′ 50.3592″N; 78° 52′ 2.658″WData accessibilityThe data is with this article

**Value of the data**•Presented data shows the relationship between pre-existing insulin secretagogues use, adipokine production at the time of cancer diagnosis and breast cancer outcomes.•This data serves as a benchmark for future investigations targeting pharmacotherapy-induced adipokine modulation in breast cancer.•The data described here can assist study design of further biomarker evaluation in relationship with the safety and effectiveness of diabetes pharmacotherapy.

1. Data {#s0005}
=======

Reported data represents the observed association between insulin secretagogues׳ utilization and the adipokine profiles at the time of breast cancer diagnosis in women with diabetes mellitus ([Table 1](#t0005){ref-type="table"}). Data in [Table 2](#t0010){ref-type="table"} includes the observed correlations between adipokines stratified by type 2 diabetes mellitus pharmacotherapy and controls.

2. Experimental design, materials and methods {#s0010}
=============================================

Evaluation of adipokine profile association with insulin secretagogue use and BC outcomes was carried out under two protocols approved by both Roswell Park Cancer Institute (EDR154409 and NHR009010) and the State University of New York at Buffalo (PHP0840409E). Demographic and clinical patient information was linked with cancer outcomes and adipokine profiles of corresponding plasma specimen harvested at BC diagnosis and banked in the Roswell Park Cancer Institute Data Bank and Bio-Repository.

2.1. Study population {#s0015}
---------------------

As described in the original research article by Wintrob et al. [@bib1], all incident breast cancer cases diagnosed at Roswell Park Cancer Institute (01/01/2003-12/31/2009) were considered for inclusion (*n*=2194). Medical and pharmacotherapy history were used to determine the baseline presence of diabetes.

2.2. Inclusion and exclusion criteria {#s0020}
-------------------------------------

Inclusion criteria were as follows: minimum 18 years of age at diagnosis, presence of pre-existing diabetes at breast cancer diagnosis, and having available banked treatment-naïve plasma specimens in the Institute׳s Data Bank and Bio-Repository. That is, the blood had to be collected prior to the initiation of any cancer-related therapy (surgery, radiation or pharmacotherapy).

Subjects were excluded if they were male, had prior cancer history or unclear date of diagnosis, incomplete clinical records, type 1 or unclear diabetes status. For a specific breakdown of excluded subjects, please see the original research article by Wintrob et al. [@bib1].

A total of 97 female subjects with breast cancer and baseline diabetes mellitus were eligible for inclusion in this analysis.

2.3. Control-matching approach {#s0025}
------------------------------

Each of the 97 adult female subjects with breast cancer and diabetes mellitus (defined as "cases") was matched with two other female subjects diagnosed with breast cancer, but without baseline diabetes mellitus (defined as "controls"). The following matching criteria were used: age at diagnosis, body mass index category, ethnicity, menopausal status and tumor stage (as per the American Joint Committee on Cancer). Some matching limitations applied [@bib1].

2.4. Demographic and clinical data collection {#s0030}
---------------------------------------------

Clinical and treatment history was documented by medical chart review. Vital status was obtained from the Institute׳s Tumor Registry, a local database updated biannually with data obtained from the National Comprehensive Cancer Networks׳ Oncology Outcomes Database. Outcomes of interest were breast cancer recurrence and/or death. For additional details concerning data collection, specific definitions regarding censoring and drug use, and a comprehensive demographic report, please see the original article [@bib1].

2.5. Plasma specimen storage and retrieval {#s0035}
------------------------------------------

All the plasma specimens retrieved from long-term storage were individually aliquoted in color coded vials labeled with unique, subject specific barcodes. Overall duration of freezing time was accounted for all matched controls ensuring that the case and matched control specimens had similar overall storage conditions. Only two instances of freeze-thaw were allowed between biobank retrieval and biomarker analyses: aliquoting procedure step and actual assay.

2.6. Enzyme-linked immunosorbent assay and Luminex® assays {#s0040}
----------------------------------------------------------

A total of 7 biomarkers (adiponectin, leptin, C-reactive protein, interleukine-6, interleukine-1β, interleukine-1Ra, tumor necrosis factor-α, and C-peptide) were quantified using either enzyme-linked immunosorbent or Luminex® assays, as described by Wintrob et al. [@bib1]. A quantitative colorimetric enzyme-linked immunosorbent assay was performed for detection of C-reactive protein, according to manufacturer protocol (Genway Biotek Inc., San Diego, CA). The following Luminex® biomarker panels were utilized in this study: human cytokine/chemokine panel I (MPXHCYTO-60K for interleukine-1β and interleukine-1Ra), human high sensitivity cytokine/chemokine panel (HSCYTO-60SK for interleukine-6 and tumor necrosis factorα), human cardiovascular disease panel I (HCVD1-67AK for adiponectin), and human endocrine panel (HENDO-65K for leptin and c-peptide) produced by Millipore Corporation, Billerica, MA.

2.7. Biomarker-pharmacotherapy association analysis {#s0045}
---------------------------------------------------

Biomarker cut-point optimization was performed for each analyzed biomarker. Biomarker levels constituted the continuous independent variable that was subdivided into two groups that optimized the log rank test among all possible cut-point selections yielding a minimum of 10 patients in any resulting group. Quartiles were also constructed. The resultant biomarker categories were then tested for association with type 2 diabetes mellitus therapy and controls by Fisher׳s exact test. The continuous biomarker levels were also tested for association with diabetes therapy and controls across groups by the Kruskall-Wallis test and pairwise by the Wilcoxon rank sum. Multivariate adjustments were performed accounting for age, tumor stage, body mass index, estrogen receptor status, and cumulative comorbidity. The biomarker analysis was performed using R Version 2.15.3. Please see the original article for an illustration of the analysis workflow [@bib1].

Correlations between biomarkers stratified by type 2 diabetes mellitus pharmacotherapy and controls were assessed by the Pearson method. Correlation models were constructed both with and without adjustment for age, body mass index, and the combined comorbidity index. Correlation analyses were performed using SAS Version 9.4.
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###### 

Adipokines associations with insulin secretagogue use.

Table 1

  Biomarker                                                Biomarker Grouping                                      Concentration   Control             No Secretagogue      Any Secretagogue    Unadjusted *p*-value (MVP)                                     
  -------------------------------------------------------- ------------------------------------------------------- --------------- ------------------- -------------------- ------------------- ---------------------------- ----------------- --------------- -----------------
  Adiponectin(ng/ml)                                       Median (25--75th)                                       --              14.9 (10.7--22.6)   11.3 (6.89--20.9)    11.7 (8.10--17.6)   \<0.015 (0.022)              0.008 (0.210)     0.810 (0.770)   0.005 (0.046)
  Quartiles                                                1.79--8.90                                              38 (19.6%)      17 (36.2%)          18 (36.0%)           0.044               0.047                        0.350             0.035           
  8.97--14.14                                              48 (24.7%)                                              12 (25.5%)      13 (26.0%)                                                                                                                  
  14.18--20.52                                             54 (27.8%)                                              6 (12.8%)       12 (24.0%)                                                                                                                  
  21.46--68.93                                             54 (27.8%)                                              12 (25.5%)      7 (14.0%)                                                                                                                   
  OS-Based Optimization                                    1.79--7.15                                              19 (9.8%)       13 (27.7%)          7 (14.0%)            0.002 (0.007)       0.390 (0.780)                0.100 (0.120)     0.005 (0.018)   
  **7.17--68.93**[⁎](#tbl1fnStar){ref-type="table-fn"}     175 (90.2%)                                             34 (72.3%)      43 (86.0%)                                                                                                                  
  DFS-Based Optimization                                   **1.79--17.91**[⁎](#tbl1fnStar){ref-type="table-fn"}    124 (63.9%)     33 (70.2%)          39 (78.0%)           0.420 (0.560)       0.060 (0.210)                0.380 (0.350)     0.150 (0.340)   
  18.21--68.93                                             70 (36.1%)                                              14 (29.8%)      11 (22.0%)                                                                                                                  
                                                                                                                                                                                                                                                                 
  Leptin (ng/ml)                                           Median (25--75th)                                       --              26.0 (16.9--38.0)   23.0 (15.4--44.1)    32.0 (21.8--50.1)   0.820 (0.330)                0.050 (0.120)     0.210 (0.700)   0.150 (0.160)
  Quartiles                                                BLQ to 17.00                                            50 (25.8%)      15 (31.9%)          8 (16.0%)            0.180               0.250                        0.180             0.190           
  17.73--27.07                                             49 (25.3%)                                              12 (25.5%)      12 (24.0%)                                                                                                                  
  27.09--41.75                                             53 (27.3%)                                              6 (12.8%)       13 (26.0%)                                                                                                                  
  43.06--159.15                                            42 (21.6%)                                              14 (29.8%)      17 (34.0%)                                                                                                                  
  OS-Based Optimization                                    **BLQ to 6.17**[⁎](#tbl1fnStar){ref-type="table-fn"}    14 (7.2%)       3 (6.4%)            1 (2.0%)             1.000 (0.640)       0.320 (0.890)                0.350 (0.740)     0.450 (0.850)   
  6.25--159.15                                             180 (92.8%)                                             44 (93.6%)      49 (98.0%)                                                                                                                  
  DFS-Based Optimization                                   BLQ to 50.82                                            155 (79.9%)     37 (79.9%)          39 (78.0%)           0.860 (0.070)       0.770 (0.002)                0.930 (0.070)     0.950 (0.002)   
  **51.64--159.15**[⁎](#tbl1fnStar){ref-type="table-fn"}   39 (20.1%)                                              10 (20.1%)      11 (22.0%)                                                                                                                  
                                                                                                                                                                                                                                                                 
  CRP (μg/ml)                                              Median (25--75th)                                       --              2.10 (0.80--4.65)   2.80 (1.10--5.30)    3.05 (1.30--9.15)   0.340 (0.670)                0.022 (0.370)     0.260 (0.890)   0.060 (0.750)
  Quartiles                                                BLQ to 0.90                                             56 (28.9%)      9 (19.1%)           9 (18.0%)            0.490               0.160                        0.770             0.340           
  1.00--2.20                                               47 (24.2%)                                              14 (29.8%)      11 (22.0%)                                                                                                                  
  2.30--5.20                                               49 (25.3%)                                              11 (23.4%)      12 (24.0%)                                                                                                                  
  5.30--23.00                                              42 (21.6%)                                              13 (27.7%)      18 (36.0%)                                                                                                                  
  OS-Based Optimization                                    BLQ to 8.30                                             173 (89.2%)     41 (87.2%)          34 (68.0%)           0.001 (0.390)       0.710 (0.580)                0.028 (0.250)     0.001 (0.530)   
  **8.60--23.00**[⁎](#tbl1fnStar){ref-type="table-fn"}     21 (10.8%)                                              6 (12.8%)       16 (32.0%)                                                                                                                  
  DFS-Based Optimization                                   BLQ to 16.60                                            186 (95.9%)     46(97.9%)           45 (90.0%)           1.000 (0.300)       0.150 (0.670)                0.210 (0.180)     0.190 (0.470)   
  **17.20--23.00**                                         8 (4.1%)                                                1 (2.1%)        5 (10.0%)                                                                                                                   
                                                                                                                                                                                                                                                                 
  IL-6 (pg/ml)                                             Median (25--75th)                                       --              0.7 (0.44--1.76)    1.49 (0.59--3.72)    1.14 (0.51--3.10)   0.010 (0.090)                0.170 (0.740)     0.330 (0.048)   0.024 (0.180)
  Quartiles                                                BLQ to 0.44                                             55 (28.4%)      7 (14.9%)           12 (24.0%)           0.027               0.190                        0.670             0.060           
  0.50--0.70                                               58 (29.9%)                                              9 (19.1%)       9 (18.0%)                                                                                                                   
  0.72--2.32                                               39 (20.1%)                                              16 (34.0%)      13 (26.0%)                                                                                                                  
  2.51--138.00                                             42 (21.6%)                                              15 (31.9%)      16 (32.0%)                                                                                                                  
  OS-Based Optimization                                    **BLQ**[⁎](#tbl1fnStar){ref-type="table-fn"}            18 (9.3%)       0 (0.0%)            1 (2.0%)             0.028 (0.010)       1.000 (0.999)                0.140 (0.300)     0.022 (0.031)   
  0.34--138.00                                             176 (90.7%)                                             47 (100%)       49 (98.0%)                                                                                                                  
  DFS-Based Optimization                                   **BLQ**[⁎](#tbl1fnStar){ref-type="table-fn"}            18 (9.3%)       0 (0.0%)            1 (2.0%)             0.028 (0.010)       1.000 (0.999)                0.140 (0.300)     0.022 (0.031)   
  0.34--138.00                                             176 (90.7%)                                             47 (100%)       49 (98.0%)                                                                                                                  
                                                                                                                                                                                                                                                                 
  TNF-α (pg/ml)                                            Median (25--75th)                                       --              5.55 (3.86--8.22)   6.64 (4.41--11.41)   6.53 (4.89--9.20)   0.060 (0.080)                0.080 (0.420)     0.850 (0.300)   0.070 (0.170)
  Quartiles                                                BLQ to 4.19                                             56 (28.9%)      9 (19.1%)           8 (16.0%)            0.060               0.260                        0.480             0.120           
  4.21--5.66                                               46 (23.7%)                                              14 (29.8%)      13 (26.0%)                                                                                                                  
  5.67--8.73                                               51 (26.3%)                                              7 (14.9%)       14 (28.0%)                                                                                                                  
  8.90--77.00                                              41 (21.1%)                                              17 (36.2%)      15 (30.0%)                                                                                                                  
  OS-Based Optimization                                    BLQ to 8.96                                             153 (78.9%)     31 (66.0%)          36 (72.0%)           0.060 (0.150)       0.300 (0.390)                0.520 (0.650)     0.150 (0.320)   
  **9.00--77.00**[⁎](#tbl1fnStar){ref-type="table-fn"}     41 (21.1%)                                              16 (34.0%)      14 (28.0%)                                                                                                                  
  DFS-Based Optimization                                   BLQ to 8.96                                             153 (78.9%)     31 (66.0%)          36 (72.0%)           0.060 (0.150)       0.300 0.390)                 0.520 (0.650)     0.150 (0.320)   
  **9.00--77.00**[⁎](#tbl1fnStar){ref-type="table-fn"}     41 (21.1%)                                              16 (34.0%)      14 (28.0%)                                                                                                                  
                                                                                                                                                                                                                                                                 
  IL-1β (pg/ml)                                            Median (25--75th)                                       --              1.60 (1.60--3.20)   1.60 (1.60--3.75)    1.60 (1.60--2.76)   0.170 (0.030)                0.140 (0.250)     0.037 (0.020)   0\. 090 (0.011)
  OS-Based Optimization                                    **BLQ to 13.08**[⁎](#tbl1fnStar){ref-type="table-fn"}   187 (96.4%)     40 (85.1%)          50 (100%)            0.008 (0.007)       0.350 (0.035)                0.005 (0.001)     0.002 (0.001)   
  14.74--127.08                                            7 (3.6%)                                                7 (14.9%)       0 (0.0%)                                                                                                                    
  DFS-Based Optimization                                   **BLQ to 13.08**[⁎](#tbl1fnStar){ref-type="table-fn"}   187 (96.4%)     40 (85.1%)          50 (100%)            0.008 (0.007)       0.350 (0.035)                0.005 (0.001)     0.002 (0.001)   
  14.74--127.08                                            7 (3.6%)                                                7 (14.9%)       0 (0.0%)                                                                                                                    
                                                                                                                                                                                                                                                                 
  C-peptide (ng/ml)                                        Median (25--75th)                                       --              1.67 (1.17--2.42)   2.36 (1.33--3.20)    2.26 (1.84--3.14    0.050 (0.760)                \<0.001 (0.041)   0.330 (0.060)   \<0.001 (0.090)
  Quartiles                                                0.14--1.28                                              58 (29.9%)      11 (23.4%)          4 (8.0%)             0.043               \<0.001                      0.140             \<0.001         
  1.29--1.82                                               59 (30.4%)                                              7 (14.9%)       7 (14.0%)                                                                                                                   
  1.83--2.68                                               37 (19.1%)                                              13 (27.7%)      22 (44.0%)                                                                                                                  
  2.68--9.02                                               40 (20.6%)                                              16 (34.0%)      17 (34.0%)                                                                                                                  
  OS-Based Optimization                                    **0.14--0.75**[⁎](#tbl1fnStar){ref-type="table-fn"}     14 (7.2%)       7 (14.9%)           0 (0%)               0.14 (0.037)        0.080 (0.130)                0.005 (0.001)     0.013 (0.008)   
  0.76--9.02                                               180 (92.8%)                                             40 (85.1%)      50 (100%)                                                                                                                   
  DFS-Based Optimization                                   **0.14--0.75**[⁎](#tbl1fnStar){ref-type="table-fn"}     14 (7.2%)       7 (14.9%)           0 (0%)               0.140 (0.037)       0.080 (0.130)                0.005 (0.001)     0.013 (0.008)   
  0.76--9.02                                               180 (92.8%)                                             40 (85.1%)      50 (100%)                                                                                                                   

C-reactive protein (CRP), interleukine-6 (IL-6), interleukine-1β (IL-1β), interleukine-1Ra (IL-1Ra), tumor necrosis factor-α (TNF-α).

Overall survival (OS)-- and disease-free survival (DFS)-optimized biomarker ranges associated with poorer outcomes are represented in bold. BLQ=below limit of quantitation. MVP=*p*-value of the multivariate adjusted analysis.

###### 

Adipokine correlations and secretagogue use.

Table 2

  Compared biomarkers         Group         Unadjusted correlation      Adjusted correlation                                                                                    
  --------------------------- ------------- --------------------------- ---------------------- ---------------------- -------------------- ------------- ---------------------- -------------
  C-peptide                   IL-1β         All Subjects (*n*=291)      −0.089                 −0.202 to 0.027        0.132                −0.081        −0.194 to 0.034        0.168
  Controls (*n*=194)          −0.003        −0.145 to 0.139             0.967                  0.01                   −0.131 to 0.151      0.891                                
  No Secretagogue (*n*=43)    −0.265        −0.532 to 0.051             0.095                  −0.285                 −0.539 to 0.017      0.061                                
  Any Secretagogue (*n*=54)   −0.069        −0.338 to 0.211             0.63                   −0.105                 −0.363 to 0.167      0.446                                
                                                                                                                                                                                  
  C-peptide                   IL-1Ra        All Subjects (*n*=291)      −0.081                 −0.195 to 0.034        0.167                −0.073        −0.187 to 0.042        0.212
  Controls (*n*=194)          −0.075        −0.214 to 0.068             0.304                  −0.063                 −0.202 to 0.079      0.382                                
  No Secretagogue (*n*=43)    −0.171        −0.458 to 0.148             0.287                  −0.18                  −0.455 to 0.128      0.245                                
  Any Secretagogue (*n*=54)   0.064         −0.215 to 0.334             0.653                  0.004                  −0.264 to 0.272      0.977                                
                                                                                                                                                                                  
  C-peptide                   IL-6          All Subjects (*n*=291)      −0.053                 −0.168 to 0.063        0.368                −0.068        −0.182 to 0.047        0.244
  Controls (*n*=194)          −0.046        −0.187 to 0.097             0.528                  −0.059                 −0.198 to 0.083      0.414                                
  No Secretagogue (*n*=43)    −0.146        −0.437 to 0.174             0.366                  −0.159                 −0.438 to 0.149      0.306                                
  Any Secretagogue (*n*=54)   −0.022        −0.295 to 0.255             0.879                  0.032                  −0.238 to 0.297      0.819                                
                                                                                                                                                                                  
  C-peptide                   Adiponectin   All Subjects (*n*=291)      **−0.163**             **−0.274 to −0.048**   **0.005**            **−0.178**    **−0.287 to −0.064**   **0.002**
  Controls (*n*=194)          **−0.145**    **−0.281 to −0.003**        **0.045**              −0.119                 −0.255 to 0.022      0.098                                
  No Secretagogue (*n*=43)    **−0.343**    **−0.591 to −0.035**        **0.028**              **−0.388**             **−0.617 to −0.1**   **0.009**                            
  Any Secretagogue (*n*=54)   −0.086        −0.353 to 0.194             0.547                  −0.068                 −0.33 to 0.203       0.621                                
                                                                                                                                                                                  
  C-peptide                   Leptin        All Subjects (*n*=291)      **0.161**              **0.047 to 0.272**     **0.006**            **0.238**     **0.126 to 0.343**     **\<0.001**
  Controls (*n*=194)          **0.278**     **0.141 to 0.404**          **\<0.001**            **0.314**              **0.181 to 0.436**   **\<0.001**                          
  No Secretagogue (*n*=43)    −0.042        −0.349 to 0.273             0.795                  −0.001                 −0.301 to 0.299      0.995                                
  Any Secretagogue (*n*=54)   0.03          −0.248 to 0.303             0.834                  0.144                  −0.129 to 0.396      0.297                                
                                                                                                                                                                                  
  C-peptide                   CRP           All Subjects (*n*=291)      −0.075                 −0.188 to 0.041        0.207                0.023         −0.092 to 0.137        0.698
  Controls (*n*=194)          −0.117        −0.254 to 0.026             0.107                  −0.042                 −0.182 to 0.099      0.556                                
  No Secretagogue (*n*=43)    0.192         −0.127 to 0.475             0.231                  0.207                  −0.099 to 0.478      0.179                                
  Any Secretagogue (*n*=54)   −0.086        −0.353 to 0.194             0.545                  --0.014                −0.281 to 0.255      0.92                                 
                                                                                                                                                                                  
  C-peptide                   TNFα          All Subjects (*n*=291)      −0.012                 −0.127 to 0.104        0.839                0.035         −0.08 to 0.15          0.55
  Controls (*n*=194)          0.086         −0.056 to 0.226             0.234                  0.125                  −0.016 to 0.261      0.082                                
  No Secretagogue (*n*=43)    −0.3          −0.559 to 0.013             0.057                  −0.277                 −0.533 to 0.026      0.069                                
  Any Secretagogue (*n*=54)   0.265         −0.011 to 0.504             0.057                  0.227                  −0.043 to 0.467      0.096                                
  IL-1β                       IL-1Ra        All Subjects (*n*=291)      **0.753**              **0.698 to 0.799**     **\<0.001**          **0.75**      **0.695 to 0.797**     **\<0.001**
  Controls (*n*=194)          **0.436**     **0.313 to 0.544**          **\<0.001**            **0.435**              **0.313 to 0.542**   **\<0.001**                          
  No Secretagogue (*n*=43)    **0.932**     **0.874 to 0.964**          **\<0.001**            **0.929**              **0.871 to 0.961**   **\<0.001**                          
  Any Secretagogue (*n*=54)   **0.367**     **0.101 to 0.583**          **0.007**              **0.384**              **0.13 to 0.591**    **0.004**                            
                                                                                                                                                                                  
  IL-1β                       IL-6          All Subjects (*n*=291)      **0.339**              **0.232 to 0.437**     **\<0.001**          **0.337**     **0.231 to 0.435**     **\<0.001**
  Controls (*n*=194)          **0.484**     **0.367 to 0.586**          **\<0.001**            **0.476**              **0.36 to 0.578**    **\<0.001**                          
  No Secretagogue (*n*=43)    **0.69**      **0.482 to 0.824**          **\<0.001**            **0.682**              **0.481 to 0.816**   **\<0.001**                          
  Any Secretagogue (*n*=54)   0.042         −0.237 to 0.314             0.771                  0.055                  −0.216 to 0.318      0.694                                
                                                                                                                                                                                  
  IL-1β                       Adiponectin   All Subjects (*n*=291)      −0.038                 −0.153 to 0.077        0.515                −0.024        −0.138 to 0.091        0.685
  Controls (*n*=194)          −0.055        −0.195 to 0.088             0.451                  −0.031                 −0.171 to 0.11       0.665                                
  No Secretagogue (*n*=43)    −0.047        −0.353 to 0.269             0.773                  −0.001                 −0.301 to 0.3        0.996                                
  Any Secretagogue (*n*=54)   −0.033        −0.306 to 0.245             0.818                  −0.054                 −0.317 to 0.217      0.695                                
                                                                                                                                                                                  
  IL-1β                       Leptin        All Subjects (*n*=291)      0                      −0.116 to 0.115        0.994                −0.009        −0.124 to 0.106        0.88
  Controls (*n*=194)          0.072         −0.071 to 0.212             0.322                  0.081                  −0.06 to 0.22        0.259                                
  No Secretagogue (*n*=43)    −0.045        −0.351 to 0.27              0.782                  −0.092                 −0.382 to 0.214      0.553                                
  Any Secretagogue (*n*=54)   −0.046        −0.317 to 0.233             0.749                  −0.202                 −0.446 to 0.069      0.14                                 
                                                                                                                                                                                  
  IL-1β                       CRP           All Subjects (*n*=291)      −0.023                 −0.139 to 0.092        0.693                −0.029        −0.143 to 0.086        0.623
  Controls (*n*=194)          −0.019        −0.16 to 0.124              0.799                  −0.01                  −0.151 to 0.131      0.891                                
  No Secretagogue (*n*=43)    0.038         −0.276 to 0.346             0.813                  −0.009                 −0.309 to 0.292      0.953                                
  Any Secretagogue (*n*=54)   −0.05         −0.322 to 0.228             0.724                  −0.14                  −0.393 to 0.133      0.31                                 
                                                                                                                                                                                  
  IL-1β                       TNFα          All Subjects (*n*=291)      **0.487**              **0.394 to 0.571**     **\<0.001**          **0.484**     **0.391 to 0.568**     **\<0.001**
  Controls (*n*=194)          **0.196**     **0.055 to 0.328**          **0.007**              **0.208**              **0.069 to 0.339**   **0.004**                            
  No Secretagogue (*n*=43)    **0.668**     **0.45 to 0.811**           **\<0.001**            **0.618**              **0.39 to 0.775**    **\<0.001**                          
  Any Secretagogue (*n*=54)   −0.065        −0.334 to 0.215             0.651                  −0.007                 −0.274 to 0.261      0.961                                
                                                                                                                                                                                  
  IL-1Ra                      IL-6          All Subjects (*n*=291)      **0.338**              **0.231 to 0.436**     **\<0.001**          **0.335**     **0.229 to 0.433**     **\<0.001**
  Controls (*n*=194)          **0.319**     **0.186 to 0.441**          **\<0.001**            **0.31**               **0.177 to 0.432**   **\<0.001**                          
  No Secretagogue (*n*=43)    **0.759**     **0.587 to 0.866**          **\<0.001**            **0.748**              **0.578 to 0.856**   **\<0.001**                          
  Any Secretagogue (*n*=54)   0.021         −0.256 to 0.295             0.882                  −0.029                 −0.294 to 0.241      0.836                                
  IL-1Ra                      Adiponectin   All Subjects (*n*=291)      −0.043                 −0.158 to 0.073        0.467                −0.049        −0.163 to 0.067        0.407
  Controls (*n*=194)          −0.013        −0.155 to 0.129             0.859                  −0.033                 −0.173 to 0.108      0.643                                
  No Secretagogue (*n*=43)    −0.077        −0.379 to 0.241             0.637                  −0.064                 −0.358 to 0.241      0.68                                 
  Any Secretagogue (*n*=54)   −0.105        −0.37 to 0.175              0.46                   −0.147                 −0.399 to 0.126      0.287                                
                                                                                                                                                                                  
  IL-1Ra                      Leptin        All Subjects (*n*=291)      0.021                  −0.095 to 0.136        0.727                0.028         −0.087 to 0.143        0.63
  Controls (*n*=194)          0.017         −0.125 to 0.159             0.812                  0.055                  −0.087 to 0.194      0.447                                
  No Secretagogue (*n*=43)    0.046         −0.269 to 0.353             0.774                  0.004                  −0.296 to 0.304      0.977                                
  Any Secretagogue (*n*=54)   −0.101        −0.366 to 0.18              0.478                  -0.131                 −0.385 to 0.142      0.344                                
                                                                                                                                                                                  
  IL-1Ra                      CRP           All Subjects (*n*=291)      0.066                  −0.05 to 0.18          0.263                0.071         −0.045 to 0.184        0.229
  Controls (*n*=194)          **0.147**     **0.005 to 0.283**          **0.042**              **0.166**              **0.026 to 0.3**     **0.02**                             
  No Secretagogue (*n*=43)    0.058         −0.259 to 0.363             0.722                  0.042                  −0.262 to b0.338     0.79                                 
  Any Secretagogue (*n*=54)   −0.081        −0.349 to 0.199             0.569                  −0.1                   −0.358 to 0.172      0.47                                 
                                                                                                                                                                                  
  IL-1Ra                      TNFα          All Subjects (*n*=291)      **0.529**              **0.441 to 0.608**     **\<0.001**          **0.516**     **0.426 to 0.596**     **\<0.001**
  Controls (*n*=194)          **0.456**     **0.336 to 0.562**          **\<0.001**            **0.449**              **0.329 to 0.555**   **\<0.001**                          
  No Secretagogue (*n*=43)    **0.623**     **0.386 to 0.782**          **\<0.001**            **0.578**              **0.335 to 0.748**   **\<0.001**                          
  Any Secretagogue (*n*=54)   0.202         −0.078 to 0.452             0.152                  0.203                  −0.068 to 0.447      0.138                                
                                                                                                                                                                                  
  IL-6                        Adiponectin   All Subjects (*n*=291)      −0.062                 −0.176 to 0.054        0.294                −0.05         −0.164 to 0.066        0.398
  Controls (*n*=194)          −0.103        −0.242 to 0.039             0.155                  −0.088                 −0.226 to 0.054      0.222                                
  No Secretagogue (*n*=43)    0.076         −0.242 to 0.378             0.64                   0.112                  −0.195 to 0.399      0.472                                
  Any Secretagogue (*n*=54)   −0.07         −0.339 to 0.209             0.623                  −0.043                 −0.307 to 0.228      0.759                                
                                                                                                                                                                                  
  IL-6                        Leptin        All Subjects (*n*=291)      0.055                  −0.061 to 0.169        0.354                0.015         −0.101 to 0.129        0.804
  Controls (*n*=194)          0.054         −0.089 to 0.195             0.457                  0.01                   −0.131 to 0.151      0.888                                
  No Secretagogue (*n*=43)    0.069         −0.248 to 0.372             0.672                  0.081                  −0.225 to 0.372      0.603                                
  Any Secretagogue (*n*=54)   0.104         −0.176 to 0.369             0.464                  0.081                  −0.191 to 0.341      0.559                                
                                                                                                                                                                                  
  IL-6                        CRP           All Subjects (*n*=291)      0.096                  −0.02 to 0.209         0.104                0.059         −0.056 to 0.173        0.315
  Controls (*n*=194)          0.141         −0.001 to 0.277             0.051                  0.095                  −0.047 to 0.233      0.188                                
  No Secretagogue (*n*=43)    −0.093        −0.394 to 0.225             0.564                  −0.09                  −0.38 to 0.216       0.562                                
  Any Secretagogue (*n*=54)   **0.302**     **0.028 to 0.533**          **0.029**              **0.268**              **0.001 to 0.5**     **0.047**                            
  IL-6                        TNFα          All Subjects (*n*=291)      **0.243**              **0.131 to 0.349**     **\<0.001**          **0.224**     **0.112 to 0.33**      **\<0.001**
                                            Controls (*n*=194)          **0.262**              **0.124 to 0.389**     **\<0.001**          **0.24**      **0.102 to 0.368**     **0.001**
                                            No Secretagogue (*n*=43)    **0.43**               **0.137 to 0.654**     **0.005**            **0.437**     **0.157 to 0.652**     **0.003**
                                            Any Secretagogue (*n*=54)   **0.309**              **0.036 to 0.539**     **0.026**            **0.304**     **0.039 to 0.528**     **0.024**
  Adiponectin                 Leptin        All Subjects (*n*=291)      −0.085                 −0.198 to 0.031        0.152                **−0.15**     **−0.261 to −0.036**   **0.01**
                                            Controls (*n*=194)          **−0.235**             **−0.365 to −0.096**   **0.001**            **−0.262**    **−0.389 to −0.126**   **\<0.001**
                                            No Secretagogue (*n*=43)    0.09                   −0.228 to 0.391        0.577                0.003         −0.298 to 0.303        0.986
                                            Any Secretagogue (*n*=54)   **0.392**              **0.131 to 0.603**     **0.004**            **0.278**     **0.011 to 0.508**     **0.04**
                                                                                                                                                                                  
  Adiponectin                 CRP           All Subjects (*n*=291)      −0.105                 −0.218 to 0.01         0.073                **−0.185**    **−0.294 to −0.072**   **0.002**
                                            Controls (*n*=194)          −0.013                 −0.154 to 0.13         0.861                −0.099        −0.237 to 0.043        0.169
                                            No Secretagogue (*n*=43)    −0.222                 −0.499 to 0.097        0.165                **−0.299**    **−0.55 to 0.002**     **0.049**
                                            Any Secretagogue (*n*=54)   **−0.32**              **−0.547 to −0.049**   **0.02**             **−0.309**    **−0.533 to −0.045**   **0.021**
                                                                                                                                                                                  
  Adiponectin                 TNFα          All Subjects (*n*=291)      −0.032                 −0.147 to 0.084        0.589                −0.009        −0.124 to 0.106        0.874
                                            Controls (*n*=194)          −0.031                 −0.172 to 0.112        0.671                0.011         −0.13 to 0.152         0.874
                                            No Secretagogue (*n*=43)    −0.025                 −0.334 to 0.289        0.878                0.019         −0.283 to 0.318        0.902
                                            Any Secretagogue (*n*=54)   −0.037                 −0.309 to 0.241        0.795                −0.031        −0.296 to 0.239        0.825
                                                                                                                                                                                  
  Leptin                      CRP           All Subjects (*n*=291)      −0.103                 −0.216 to 0.013        0.08                 0.114         −0.001 to 0.226        0.051
                                            Controls (*n*=194)          **−0.151**             **−0.287 to −0.009**   **0.036**            0.07          −0.072 to 0.208        0.334
                                            No Secretagogue (*n*=43)    −0.141                 −0.433 to 0.178        0.382                0.165         −0.142 to 0.443        0.286
                                            Any Secretagogue (*n*=54)   −0.052                 −0.323 to 0.227        0.714                0.173         −0.099 to 0.421        0.208
                                                                                                                                                                                  
  Leptin                      TNFα          All Subjects (*n*=291)      0.087                  −0.029 to 0.2          0.142                **0.127**     **0.012 to 0.238**     **0.03**
                                            Controls (*n*=194)          0.03                   −0.112 to 0.171        0.679                0.094         −0.048 to 0.231        0.193
                                            No Secretagogue (*n*=43)    0.082                  −0.236 to 0.384        0.613                0.208         −0.099 to 0.478        0.178
                                            Any Secretagogue (*n*=54)   0.214                  −0.065 to 0.463        0.128                0.068         −0.203 to 0.33         0.623
                                                                                                                                                                                  
  TNFα                        CRP           All Subjects (*n*=291)      0.021                  −0.095 to 0.136        0.721                0.056         −0.059 to 0.17         0.337
                                            Controls (*n*=194)          0.101                  −0.042 to 0.24         0.164                0.136         −0.005 to 0.271        0.058
                                            No Secretagogue (*n*=43)    0.032                  −0.282 to 0.34         0.843                0.072         −0.233 to 0.365        0.644
                                            Any Secretagogue (*n*=54)   −0.076                 −0.344 to 0.204        0.595                −0.126        −0.381 to 0.147        0.361

Significant correlations are displayed in bolded text. The differences that are only significant in either adjusted or unadjusted correlations are further denoted by an outline. C-reactive protein (CRP), interleukine-6 (IL-6), interleukine-1β (IL-1β), interleukine-1Ra (IL-1Ra), tumor necrosis factor-α (TNF-α), confidence interval (CI).
